A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting now

Conditions studied: Thrombotic Thrombocytopenic Purpura (TTP)

In brief

This study is a survey in Japan of recombinant ADAMTS13 used to treat or to prevent participants with congenital thrombotic thrombocytopenic purpura (cTTP). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from recombinant ADAMTS13 and to check if recombinant ADAMTS13 improves or prevents cTTP. During the study, participants with cTTP will take recombinant ADAMTS13 intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from recombinant ADAMTS13 for 18 months.

Key facts

Study ID

NCT06441578

Run by

Takeda

People needed

40

Starts

2024-05-30

Expected to finish

2032-09-30

Last updated by the study team

2025-10-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All participants with congenital thrombotic thrombocytopenic purpura (cTTP), treated with recombinant ADAMTS13

You may not qualify if…

• None

Where it is running

• Takeda selected site — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.